Therapeutic Effects of Paclitaxel (Taxol ) in Metastatic Breast Cancer
Journal of the Korean Surgical Society
;
: 509-514, 1999.
Artigo
em Coreano
| WPRIM
| ID: wpr-145709
ABSTRACT
BACKGROUND:
Metastatic breast cancer is a systemic disease, and its treatment aims at the palliation or cure of the disease. In recent years, good results have been reported in the treatment of metastatic breast cancer by using single-agent paclitaxel chemotherapy.METHODS:
We performed a retrospective study by analyzing the medical records of patients treated at Kangnam St. Mary's Hospital between May 1995 and May 1997. A total of 29 patients with metastatic breast cancer were treated by a 135-mg/m2, 3-hour infusion of paclitaxel. The results were reviewed with respect to the response rates and the toxicities of paclitaxel.RESULTS:
The overall response rate was 13.8% CR (complete response rate) 3.4% (1 out of 29) and PR (partial response rate) 10.3%(3 out of 29). The most common and severe toxicity was leukopenia. However, there was no mortality, and the patients were tolerated this therapy.CONCLUSIONS:
Paclitaxel as a single-agent therapy for metastatic breast cancer is tolerable, but less effective, than reported.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Mama
/
Neoplasias da Mama
/
Prontuários Médicos
/
Estudos Retrospectivos
/
Mortalidade
/
Paclitaxel
/
Tratamento Farmacológico
/
Leucopenia
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Surgical Society
Ano de publicação:
1999
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS